Whole genome sequencing rarely alters treatment plans, except for identifying mutations like Tom 40 that indicate Alzheimer's risk.

“so I've had a number of patients I mean at least half my patients over the last few years have have either done a whole sequence or at the very least done you know something like 23andme and we run that through Prometheus and I'm trying to think of a single time when anything in there altered our treatment plan beyond what we already knew maybe the odd patient that shows up with a Tom 40 mutation who was otherwise in a po 33 that you think okay you're probably a little higher risk than we thought for Alzheimer's”